MacroGenics
Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 350
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (MGNX)
- Website
- macrogenics.com
- Company page
What is happening at MacroGenics
The most recent event Fundz has on record for MacroGenics is dated Nov 13, 2026: On November 13, 2026, MacroGenics, Inc. provided an updated corporate presentation on its website, detailing new clinical program information. This disclosure is categorized under Regulation FD, which emphasizes that .... In the 12 months to Nov 17, 2026 Fundz recorded 9 dated events for MacroGenics: 7 SEC 8-K filings and 2 deals as the target.
- · SEC 8-K filing: On November 13, 2026, MacroGenics, Inc. provided an updated corporate presentation on its website, detailing new clinical program information. This disclosure is categorized under Regulation FD, which emphasizes that ...
- · SEC 8-K filing: On October 30, 2026, MacroGenics, Inc.'s Board of Directors approved an increase in the board size from ten to eleven members. The Board appointed Michael Vasconcelles as a Class II Director and Emil Kuriakose as a Cl...
- · SEC 8-K filing: On October 23, 2026, MacroGenics, Inc. announced interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate for patients with advanced solid tumors. This announcement include...
- · SEC 8-K filing: On July 23, 2026, MacroGenics, Inc. provided a clinical update regarding its ongoing Phase 1 study of MGC026. The press release, attached as Exhibit 99.1, highlights new findings and developments in the clinical trial...
- · Acquired: Bora Pharmaceuticals acquires MacroGenics' operations
- · Acquired: Gilead Sciences to acquire MacroGenics for $1.7B
- · SEC 8-K filing: On May 11, 2026, MacroGenics, Inc. entered into a Material Definitive Agreement with Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC, to sell its GMP manufacturing operations, particularly its CDMO business...
- · SEC 8-K filing: On May 1, 2026, MacroGenics, Inc. entered into a First Amendment to the Royalty Purchase Agreement with Sagard Healthcare Partners, resulting in an additional cash payment of $60.0 million, raising the total purchase ...
- · SEC 8-K filing: On April 8, 2026, MacroGenics, Inc. announced via press release that the U.S. FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational bispecific DART® molecule designed...
- · Executive change: MacroGenics Appoints Eric Risser as President and Chief Executive Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise. As of Nov 17, 2026.
Timing is half of it. See who you already know at MacroGenics
Leadership
- Eric Risser, Chief Executive Officer
Verified email and direct lines for MacroGenics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
MacroGenics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
MacroGenics in the news
- MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewswire (May 11, 2026)
- Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study - BioSpace (Feb 25, 2026)
- MacroGenics closes solid tumor clinical trial after 7 people die - Fierce Biotech (Jul 11, 2022)
- MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha (Sep 09, 2026)
- MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement - Yahoo Finance (May 04, 2026)
- Janssen drops MacroGenics cancer candidate over safety concerns - BioPharma Dive (Sep 01, 2017)
- MacroGenics - Nature (Dec 31, 2017)
- MacroGenics' stock crashes after 5 deaths in ADC trial - Fierce Biotech (May 10, 2024)
Companies similar to MacroGenics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About MacroGenics: questions and answers
What is happening at MacroGenics?
The most recent event Fundz has on record for MacroGenics is dated Nov 13, 2026: On November 13, 2026, MacroGenics, Inc. provided an updated corporate presentation on its website, detailing new clinical program information. This disclosure is categorized under Regulation FD, which emphasizes that .... In the 12 months to Nov 17, 2026 Fundz recorded 9 dated events for MacroGenics: 7 SEC 8-K filings and 2 deals as the target.
What does MacroGenics do?
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Where is MacroGenics headquartered?
MacroGenics is headquartered in Rockville, Maryland, United States.
How many employees does MacroGenics have?
MacroGenics has about 350 employees.
Who leads MacroGenics?
Eric Risser is a Chief Executive Officer at MacroGenics.
Is MacroGenics a public company?
Yes. MacroGenics is publicly traded under the ticker MGNX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy